12:00 AM
Jun 16, 2008
 |  BioCentury  |  Strategy

Infectious symphony

Infectious symphony

By Mike Ward Senior Editor

Genentech Inc. made its first announced foray into the infectious disease space last week when it acquired exclusive licenses from Symphogen A/S to two antibody-related technology platforms against three undisclosed targets.

In March, Genentech said it was planning to build on its strengths in protein and antibody engineering to create an infectious diseases franchise. At the time, Andrew Chan, SVP of research immunology and antibody engineering, said Genentech's focus would include CMV, HCV, HIV, Candida albicans, tuberculosis (TB) and Staphylococcus aureus. But since then, the company has said little about its plans.

Indeed, Genentech has been keeping at least one deal under wraps, as spokesperson Kelli Wilder told BioCentury that the Symphogen relationship was the first to be disclosed.

The deal with the Danish company adds two discovery technologies to Genentech's in-house antibody capabilities: Symphogen's Symplex antibody discovery technology platform and its Sympress technology to produce...

Read the full 755 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >